CA
NZ
UK
AU
IND
US
REGENXBIO Inc. filed an 8-K with the SEC on September 23, 2026, disclosing that it and the University of Pennsylvania entered into a Settlement Agreement with Sarepta Therapeutics and Catalent, Inc. to resolve all patent infringement litigation related to the gene therapy product ELEVIDYS.
Mobile Infrastructure Corporation filed a Form 8-K on September 23, 2026, disclosing a fifth amendment to its credit agreement that extends the maturity date to December 31, 2026, and the declaration of monthly dividends on two series of preferred stock.
Eva Live Inc. filed a Form 8-K with the SEC on September 23, 2026, disclosing that on September 17, 2026, the company entered into an Equity Purchase Agreement, a Registration Rights Agreement, and issued a Common Stock Purchase Warrant to Hudson Global Ventures, LLC.
Zymeworks Inc. filed a current report on September 23, 2026, disclosing the completion of its merger with Theravance Biopharma, Inc., along with the entry into a Contingent Value Rights Agreement and a $350,000,000 senior secured notes financing transaction.
Evommune, Inc. filed a current report on Form 8-K on September 23, 2026, disclosing that the company issued a press release announcing a late-breaker presentation of Phase 2a data for its EVO301 program in atopic dermatitis at the European Academy of Dermatology and Venereology …
Gossamer Bio, Inc. filed a current report on Form 8-K on September 23, 2026, announcing that it submitted a New Drug Application to the U.S. Food and Drug Administration for seralutinib for the treatment of pulmonary arterial hypertension.
Galaxy Digital Inc. filed a current report on September 23, 2026, disclosing the appointment of Dritan Muneka as Corporate Controller and principal accounting officer, effective September 30, 2026, following the resignation of Robert Rico.
Visa Inc. filed a Form 8-K with the SEC on September 23, 2026, disclosing that on September 18, 2026, it authorized a $405 million deposit into the U.S. litigation escrow account established under its U.S. retrospective responsibility plan, triggering downward adjustments to the conversion …
Ready Capital Corporation filed a Form 8-K on September 23, 2026, disclosing that on September 18, 2026, it entered into an amendment to the indenture governing its 7.375% Senior Notes due 2027, modifying key financial covenants with the consent of a majority of noteholders.
Sarepta Therapeutics, Inc. filed an 8-K on September 23, 2026, disclosing that it entered into a settlement agreement with REGENXBIO Inc., the Trustees of the University of Pennsylvania, and Catalent, Inc. to resolve pending patent infringement litigations related to two U.S. patents.
Please wait processing your request...